Wearable Medical Devices Market to grow by USD 15.54 billion from 2022 to 2027 | Market is Fragmented Due to the Presence of Prominent Companies Like Abbott Laboratories, Alphabet Inc., Apple Inc. & More

Wearable Medical Devices Market

The wearable medical devices market is estimated to grow by USD 15.54 billion from 2022 to 2027, growing at a CAGR of 17.82%. The wearable medical devices market is fragmented owing to the presence of many global and regional companies. A few prominent companies that offer wearable medical devices market are 3L Labs Co. Ltd., Abbott Laboratories, Alphabet Inc., Apple Inc., Biotricity Inc., Boston Scientific Corp., Daifuku Co. Ltd., Dexcom Inc., Garmin Ltd., General Electric Co., Huawei Technologies Co. Ltd., Johari Digital India Ltd., Koninklijke Philips N.V., Medtronic Plc, OMRON Corp., Oura Health Oy, Polar Electro Oy, Samsung Electronics Co. Ltd., The Sotera Wireless Inc., and ten3T Healthcare.

The report provides a full list of key companies, their strategies, and the latest developments.

Company Offering:

  • Abbott Laboratories – The company offers wearable medical devices such as wearable FreeStyle Libre devices.
  • Alphabet Inc. – The company offers wearable medical devices such as the Fitbit series under its subsidiary called Google LLC.
  • Apple Inc. – The company offers wearable medical devices such as the Apple Watch series to measure blood oxygen levels.
  • For details on companies and their offerings – Buy the report!

By Geography, the market is classified as North America, Europe, Asia, and Rest of World (ROW). North America will have the largest share of the market. The region is estimated to contribute 37% to the growth of the global market during the forecast period. The rising incidence of diseases, a high prevalence of hearing impairment, an increase in the number of technological devices used for wearables, increasing GDP, increased healthcare spending, new product launches and significant market presence of large companies are some of the major factors driving the growth in the region.

  • Impactful driver- Increasing prevalence of chronic diseases globally
  • Key Trend – Emergence of innovative wearable medical devices
  • Major Challenges – High cost of wearable medical devices

Market Segmentation

  • The diagnostic and monitoring devices segment is estimated to witness significant growth during the forecast period. These devices enable the detection and monitoring of changes in body signatures throughout various areas and organs, thus making them a major advantage. Furthermore, factors such as the increasing health consciousness among end-users, the launch of low-cost wearable vital signs and activity monitoring devices, and technological advancements are also positively impacting the growth of this segment.
  • Related Reports:The diagnostic wearable medical devices market size is estimated to grow by USD 7,333.3 million at a CAGR of 15.2% between 2022 and 2027.The wearable pulse oximeters market is estimated to grow by USD 244.66 million at a CAGR of 7.3% between 2023 and 2027.
SourceTechnavio

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”